CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X

[1]  H. Blum,et al.  Hepatitis B Virus-Infected HepG2hNTCP Cells Serve as a Novel Immunological Tool To Analyze the Antiviral Efficacy of CD8+ T Cells In Vitro , 2015, Journal of Virology.

[2]  J. Fu,et al.  Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus , 2015, Gene Therapy.

[3]  B. Cullen,et al.  Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. , 2015, Virology.

[4]  Xiaoling Wang,et al.  Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors , 2015, Nature Biotechnology.

[5]  Richard L. Frock,et al.  Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases , 2014, Nature Biotechnology.

[6]  C. Seeger,et al.  Targeting Hepatitis B Virus With CRISPR/Cas9 , 2014, Molecular therapy. Nucleic acids.

[7]  A. Bertoletti,et al.  Hepatitis B: future curative strategies , 2014, Current opinion in infectious diseases.

[8]  J. Jang,et al.  Update on hepatitis B virus infection. , 2014, World journal of gastroenterology.

[9]  R. Samulski,et al.  AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. , 2014, Annual review of virology.

[10]  Ding-Shinn Chen,et al.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo , 2014, Molecular therapy. Nucleic acids.

[11]  S. Kottilil,et al.  Strategies to eliminate HBV infection. , 2014, Future virology.

[12]  Jinhong Chang,et al.  Therapeutic strategies for a functional cure of chronic hepatitis B virus infection , 2014, Acta pharmaceutica Sinica. B.

[13]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[14]  Mazhar Adli,et al.  Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease , 2014, Nature Biotechnology.

[15]  Gang Bao,et al.  CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences , 2014, Nucleic acids research.

[16]  M. Sunbul.  Hepatitis B virus genotypes: global distribution and clinical importance. , 2014, World journal of gastroenterology.

[17]  J. Schiffer,et al.  AAV-Mediated Delivery of Zinc Finger Nucleases Targeting Hepatitis B Virus Inhibits Active Replication , 2014, PloS one.

[18]  K. Jerome,et al.  DNA cleavage enzymes for treatment of persistent viral infections: recent advances and the pathway forward. , 2014, Virology.

[19]  T. Liang,et al.  Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA , 2014, Science.

[20]  V. Iyer,et al.  Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects , 2014, Nature Methods.

[21]  Zhenghong Yuan,et al.  An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  Hussein H. Aly,et al.  Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP. , 2014, Biochemical and biophysical research communications.

[23]  Jin-Soo Kim,et al.  Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases , 2014, Genome research.

[24]  Hao Hu,et al.  Adenoviral Delivery of Recombinant Hepatitis B Virus Expressing Foreign Antigenic Epitopes for Immunotherapy of Persistent Viral Infection , 2013, Journal of Virology.

[25]  David A. Scott,et al.  Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity , 2013, Cell.

[26]  Wenhui Li,et al.  Alpha-Interferon Suppresses Hepadnavirus Transcription by Altering Epigenetic Modification of cccDNA Minichromosomes , 2013, PLoS pathogens.

[27]  A. Schambach,et al.  Highly Significant Antiviral Activity of HIV-1 LTR-Specific Tre-Recombinase in Humanized Mice , 2013, PLoS pathogens.

[28]  M. Yuen,et al.  Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  G. Church,et al.  CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering , 2013, Nature Biotechnology.

[30]  T. Cathomen,et al.  Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  W. Gerlich.  Medical Virology of Hepatitis B: how it began and where we are now , 2013, Virology Journal.

[32]  C. Barbas,et al.  ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. , 2013, Trends in biotechnology.

[33]  Daniel Stone,et al.  Predictors of Hepatitis B Cure Using Gene Therapy to Deliver DNA Cleavage Enzymes: A Mathematical Modeling Approach , 2013, PLoS Comput. Biol..

[34]  J. Keith Joung,et al.  High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells , 2013, Nature Biotechnology.

[35]  R. Gish,et al.  Chronic hepatitis B: what should be the goal for new therapies? , 2013, Antiviral research.

[36]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[37]  Alan Kay,et al.  HBVdb: a knowledge database for Hepatitis B Virus , 2012, Nucleic Acids Res..

[38]  F. Zoulim.  Are novel combination therapies needed for chronic hepatitis B? , 2012, Antiviral research.

[39]  Percy A. Knolle,et al.  Living in the liver: hepatic infections , 2012, Nature Reviews Immunology.

[40]  Jin-Soo Kim,et al.  Surrogate reporters for enrichment of cells with nuclease-induced mutations , 2011, Nature Methods.

[41]  N. Brunetti‐Pierri,et al.  Helper-dependent adenoviral vectors for liver-directed gene therapy. , 2011, Human molecular genetics.

[42]  Ting Chang,et al.  Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents , 2011, Journal of medical virology.

[43]  C. Thio,et al.  Review of hepatitis B therapeutics. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  W. Wurst,et al.  Gene targeting by homologous recombination in mouse zygotes mediated by zinc-finger nucleases , 2010, Proceedings of the National Academy of Sciences.

[45]  A. McCaffrey,et al.  Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  P. Hainaut,et al.  Worldwide genetic diversity of HBV genotypes and risk of hepatocellular carcinoma. , 2009, Cancer letters.

[47]  M. Levrero,et al.  Control of cccDNA function in hepatitis B virus infection. , 2009, Journal of hepatology.

[48]  C. Chu,et al.  Hepatitis B virus infection , 2009, The Lancet.

[49]  Michael Hallek,et al.  Recent developments in adeno‐associated virus vector technology , 2008, The journal of gene medicine.

[50]  D. Tyrrell,et al.  Zinc Finger Proteins Designed To Specifically Target Duck Hepatitis B Virus Covalently Closed Circular DNA Inhibit Viral Transcription in Tissue Culture , 2008, Journal of Virology.

[51]  T. Block,et al.  Molecular virology of hepatitis B virus for clinicians. , 2007, Clinics in liver disease.

[52]  P. Schirmacher,et al.  Antiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection. , 2007, Gastroenterology.

[53]  M. Feitelson,et al.  Hepatitis B virus integration, fragile sites, and hepatocarcinogenesis. , 2007, Cancer letters.

[54]  H. Gu,et al.  Inhibition of Hepatitis B virus cccDNA replication by siRNA. , 2007, Biochemical and biophysical research communications.

[55]  W. Huttner,et al.  Single-cell detection of microRNAs in developing vertebrate embryos after acute administration of a dual-fluorescence reporter/sensor plasmid. , 2006, BioTechniques.

[56]  J. Koskinas,et al.  Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients , 2006, Hepatology.

[57]  F. Zoulim.  Antiviral Therapy of Chronic Hepatitis B: Can We Clear the Virus and Prevent Drug Resistance? , 2004, Antiviral chemistry & chemotherapy.

[58]  M. Bouchard,et al.  The Enigmatic X Gene of Hepatitis B Virus , 2004, Journal of Virology.

[59]  P. Coursaget,et al.  Genetic Diversity of Hepatitis B Virus Strains Derived Worldwide: Genotypes, Subgenotypes, and HBsAg Subtypes , 2004, Intervirology.

[60]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[61]  Yingchen,et al.  HBV cccDNA in patients＇ sera as an indicator for HBV reactivation and an early signal of liver damage , 2004 .

[62]  M. Westphal,et al.  Oncoretrovirus and Lentivirus Vectors Pseudotyped with Lymphocytic Choriomeningitis Virus Glycoprotein: Generation, Concentration, and Broad Host Range , 2002, Journal of Virology.

[63]  E. ten Dam,et al.  The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. , 2001, The Journal of general virology.

[64]  D. Trono,et al.  A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.

[65]  Ding‐Shinn Chen,et al.  Hepatitis B Virus Infection , 2007 .

[66]  G. Acs,et al.  Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. , 1987, Proceedings of the National Academy of Sciences of the United States of America.